Search research articles
Contact Us
Filters
Showing results (11-20 of 33) with videos related to
Page
of 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi
Umberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
British Journal of Haematology
|
January 21, 2021
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
Carola Boccomini, Marco Ladetto, Luigi Rigacci, et al.
Annals of Hematology
|
March 13, 2025
Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study
Alessia Castellino, Lorenzo Comba, Laura Bertolotti, et al.
Eclinicalmedicine
|
October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
Urban Novak, Martin Fehr, Sämi Schär, et al.
Thrombosis and Haemostasis
|
April 28, 2017
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)
Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, et al.
British Journal of Haematology
|
November 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial
Giulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
Ejhaem
|
July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
Vincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Blood
|
October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
Marco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
Ejhaem
|
July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
Loretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
Blood
|
August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 33) with videos related to
Sort By:
Page
of 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi
Umberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
British Journal of Haematology
|
January 21, 2021
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
Carola Boccomini, Marco Ladetto, Luigi Rigacci, et al.
Annals of Hematology
|
March 13, 2025
Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study
Alessia Castellino, Lorenzo Comba, Laura Bertolotti, et al.
Eclinicalmedicine
|
October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
Urban Novak, Martin Fehr, Sämi Schär, et al.
Thrombosis and Haemostasis
|
April 28, 2017
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)
Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, et al.
British Journal of Haematology
|
November 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial
Giulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
Ejhaem
|
July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
Vincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Blood
|
October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
Marco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
Ejhaem
|
July 18, 2022
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
Loretta J Nastoupil, John Kuruvilla, Julio C Chavez, et al.
Blood
|
August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
Page
of 4